期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

DLC-1蛋白在非小细胞肺癌组织中的表达及临床意义

下载PDF
导出
摘要 目的探讨肝癌缺失基因(DLC-1)蛋白在非小细胞肺癌(NSCLC)发生、发展中的作用。方法选择手术切除的NSCLC组织标本40份(肿瘤组),癌旁组织标本40份(癌旁组),采用免疫组化法检测两组NSCLC蛋白表达情况,并分析其与NSCLC临床病理特征的相关性。结果肿瘤组及癌旁组DLC-1蛋白阳性率分别为42.5%(17/40)、0,P<0.05;DLC-1蛋白表达与病理分期、淋巴结转移及肿瘤分化程度相关,而与性别、组织类型、肿瘤大小无关。结论 DLC-1蛋白在NSCLC的发生、发展中起重要作用。
作者 杨春香 张晴菊 顾国浩
机构地区 无锡市第三人民医院 苏州大学附属第一医院
出处 《山东医药》 CAS 2012年第35期46-47,共2页 Shandong Medical Journal
关键词 肝癌缺失基因蛋白 免疫组织化学 癌 非小细胞肺
分类号 R730.3 [医药卫生—肿瘤]
  • 相关文献

参考文献6

  • 1于世英.肺癌分子靶向治疗药物的研究进展[J].医药导报,2006,25(7):654-656. 被引量：11
  • 2Liao YC, Si L, Devere White RW, et al. The phosphotyrosine-inde- pendent interaction of DLC-1 and the SH2 domain of cten regulates focal adhesion localization and growth suppression activity of DLC-1 [J]. J Cell Biol, 2007,176(1) :43-49.
  • 3Seng TJ, Low JS, Li H, et al. The major 8p22 tumor suppressor DLC-1 is frequently silenced by methylation in both endemic and sporadic nasopharyngeal, esophageal, and cervical careinomas, and inhibits tumor cell colony formation [ J ]. Oncogene, 2007,26 (6) : 934-944.
  • 4Yuan BZ, Jefferson AM, Baldwin TK, et al. DLC-1 operates as a tunlor suppressor gene in human non-small cell lung carcinomas [J]. Oncogene, 2004,23(7) :1405-1411.
  • 5Wong CM, Lee JM, Ching YP, et al. Genetic and epigenetie alter- atiousof DLC-1 gene in hepatoeellular carcinoma[J]. Cancer Res, 2003,22 (63) :7646-7651.
  • 6Healy KD, Hodgson I, Kim TY, et al. DLC-1 suppresses non-smal cell lung cancer growth and invasion by Rho GAP dependent and in- dependent mechanisms [ J]. Mol Carcinog, 2008,47 (5) :326-337.

二级参考文献16

  • 1Hotta K,Kiuya K,Ueoka H,et al.Effect of gefitinib (Iressa,ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer[J].Lung Cancer,2004,46(2):255-261.
  • 2Herbst R S,Prager D,Hermawn R,et al.Tribute:a phase Ⅲ trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer[J].J Clin Oncol,2005,23(25):5892-5899.
  • 3Paez J G,Janne P A,Lee J C,et al.EGFR mutations in lung cancer:correla-tion with clinical response to gefitinib therapy[J].Science,2004,304(5676):1497-1500.
  • 4Pao W,Miller V,Zakowski M,et al.EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib[J].Proc Natl Acad Sci USA,2004,101(36):13306-13311.
  • 5Lynch T J,Bell D W,Soldella R,et al.Activating mutations in the epidermal grow-th factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib[J].N Engl J Med,2004,350(21):2129-2139.
  • 6Kosaka T,Yatabe Y,Endon H,et al.Mutations of the epidermal growth factor receptor gene in lung cancer[J].Cancer Res,2004,64(24):8919-8923.
  • 7Huang S F,Liu H P,Li L H,et al.High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan[J].Clin Cancer Res,2004,10(24):8195-8203.
  • 8Kobayashi S,Boggon,Dayaram T,et al.EGFR mutation and resis-tance of non-small-cell lung cancer to gefitinib[J].N Engl J Med,2005,352(8):786-792.
  • 9Belvedere O,Grossi F.Lung cancer highlights from ASCO 2005[J].Oncologist,2006,11(1):39-50.
  • 10Dornbusch D,Allegra C,Willey J,et al.How do U.S.medical onco-logists learn and apply new clinical trials information from press releases in nonmedical media? a case study based on ECOG 4599[J].Oncologist,2006,11(1):31-38.

共引文献10

山东医药
2012年 第35期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部